THE REAL PREVALENCE OF EROSIVE ESOPHAGITIS AND BARRETT'S ESOPHAGUS IN SYSTEMIC SCLERODERMA: DATA FROM 12-MONTHS PROSPECTIVE STUDY

Complicated forms of reflux-esophagitis, i.e., erosive esophagitis and Barrett's esophagus (BE) — are common types of visceral pathology in systemic scleroderma (SSD), which require adequate therapy and follow up. Although real prevalence of esophageal involvement in SSD in Russian patients remains uncertain. Objective — to identify prevalence of erosive esophagitis and BE, and to quantify gastro-intestinal (GI) symptoms in patients with SSD. Material and methods. During 1 year (December 2009 — January 2011) all consecutive SSD patients, hospitalized to FSBI «SRIR» RAMS, after signing informed consent, were subjected to esophagogastroduodenoscopy with biopsy of esophageal mucosa in upper 1/3. Totally 123 patients were examined (96,8% females, 3,2% males, aged 50,5±13,1 years). Esophageal mucous was evaluated for presence of pathologic changes and BE (intestinal metaplasia in biopsy samples was a BE diagnostic criterion). SODA questionnaire was used to quantify GIT symptoms Results. Erosive esophagitis was detected in 30 (24,3%) patients, BE — in 11 (8,9%). In 80% of patients marked changes in esophageal mucosa were associated with typical symptoms (heartburn, regurgitaion, dysphagia), while in some cases (in 3 patients) erosive esophagitis and BE were asymptomatic. Quantitative evaluation of symptoms with SODA questionnaire demonstrated clear correlation between subjective assessment and severity of esophageal pathologic changes. In patients with erosive gastritis and BE the SODA «pain» and «non-pain» parameters scores were significantly higher and satisfaction in dyspepsia management was lower (p<0,05), then in individuals without erosions and mucosal inflammation. Here was no clear correlation between esophageal pathology and SSD type (limited, diffuse), age, duration of the disease, presence of pulmonary interstitial lesion and Sjogren's syndrome. Patients with erosive esophagitis were significantly more often (36,6%) using proton pomp inhibitors as compared to individuals without apparent esophageal pathology (22,0%; p<0,001). Conclusion. Erosive esophagitis is diagnosed in each 4th patient with SSD.EB is also quite common in this pathology, predetermining the necessity of regular endoscopic check-ups in all SSD patients. SODA questionnaire is a useful tool to evaluate the severity of upper GIT symptoms in SSD patients during follow up.

systemic scleroderma, esophagitis, Barrett's esophagus, proton pomp inhibitors, SODA questionnaire

1. <div><p>Ревматология. Клинические рекомендации. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2010; 752 с.</p><p>Ebert E. Esophageal disease in progressive systemic sclerosis. Curr Treat Options Gastroenterol 2008; 11(1): 64—9.</p><p>Ntoumazios S., Voulgari P., Potsis K. et al. Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem. Semin Arthr Rheum 2006; 36(3): 173—81.</p><p>Kowal-Bielecka O., Landewe R., Avouac J. et al. EULAR recommendation for the treatment of systemic sclerosis: a report from the EULAR scleroderma trials and research group (EUROSTAR). Ann Rheum Dis 2009; 68(50): 620—9.</p><p>Wipff J., Coriat R., Masciocchi M. et al. Outcomes of Barrett's oesophagus related to systemic sclerosis: a 3-year EULAR Scleroderma Trials and Research prospective follow-up study. Rheumatology (Oxford) 2011, Mar 16 [Epub. ahead of print]</p><p>Rabeneck L., Cook K., Wristers K. et al. SODA (severity of dyspepsia assessment): a new effective outcome measure for dyspepsia-related health. J Clin Epidemiol 2001; 54(8): 755—65.</p><p>Roberts D., Miner P. Safety aspects and rational use of a naproxen + esomeprazole combination in the treatment of rheumatoid disease. Drug Healthc Patient Saf 2011; 3: 1—8.</p><p>Лазебник Л.Б., Дроздов В.Н., Ким В.А. Эффективность фамотидина в профилактике НПВП-гастропатий. Результаты российского многоцентрового исследования ЗАСЛОН-1 (защита слизистой оболочки желудка от нестероидных противовоспалительных препаратов). Экпер. клин. гастроэнтерол. 2009; 2: 3—9.</p><p>Калинин А.В. Гастроэзофагеальная рефлюксная болезнь: диагностика, терапия и профилактика. Фарматека 2003; 7: 23—9.</p><p>Paull A., Trier J., Dalton M. et al. The histologic spectrum of Barrett's esophagus. N Engl J Med 1976; 295: 476—80.</p><p>Kilgore S., Ormsby A., Gramlich T. The gastric cardia: fact or fiction? Amer J Gastroenterol 2000; 95: 91—4.</p><p>Quiglet E. The gastroesophageal junction revision: Perspectives in GERD. World Gastroenterol News 2000; 5: 25—8.</p><p>Weingart V., Allescher H. Non-cardiac chest pain. Dtsch Med Wschr 2010; 135(43): 2135—46.</p><p>Miwa H., Kondo T., Oshima T. et al. Esophageal sensation and esophageal hypersensitivity — overview from bench to bedside. J Neurogastroenterol Motil 2010; 16(4): 353—62.</p><p>Nishimagi E., Tochimoto A., Kawaguchi Y. et al. Characteristics of patients with early systemic sclerosis and severe gastrointestinal tract involvement. J Rheumatol 2007; 34(10): 2050—5.</p><p>Lahcene M., Oumnia N., Matougui N. et al. Esophageal involvement in scleroderma: clinical, endoscopic, and manometric features. ISRN Rheumatol 2011; doi: 10.5402/2011: 325826.</p><p>Алекперов Р.Т., Каратеев А.Е., Гусева Н.Е Ланзап в лечении склеродермического эзофагита. Науч.-практич. ревматол. 2003; 2: 25—8.</p><p>Marie I., Ducrotte P., Denis P. et al. Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy. Aliment Pharmacol Ther 2006; 24(11—12): 1593—601.</p><p>Каратеев А.Е., Мовсисян М.М., Ананьева Л.П., Раденска-Лоповок С.Г. Патология пищевода при системной склеродермии: данные клинико-эндоскопического обследования. Науч.-практич. ревматол. 2012; 1: 54—9.</p><p>Marie I. Gastrointestinal involvement in systemic sclerosis. Presse Med 2006; 35(12 Pt 2): 1952—65.</p><p>Santos-Navarro R., Mendez-del-Monte R., del Real-Calzada C., Vera-Lastra O. Clinical, endoscopic and manometric findings in the gastroesophageal tract of patients with systemic sclerosis. Rev Med Inst Mex Seguro Soc 2008; 46(5): 503—10.</p><p>Wipff J., Allanore Y., Soussi F. et al. Prevalence of Barrett's esophagus in systemic sclerosis. Arthr Rheum 2005; 52(9): 2882—8.</p></div><br />